Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 19/20 | 1.00 |
| ▸ | LCK | P06239 | 18/20 | 1.00 |
| ▸ | EGFR | P00533 | 9/20 | 1.00 |
| ▸ | BTK | Q06187 | 7/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16763889 | 1.00 | JAK3 (1.00) | JAK3LCKEGFRBTK | |
| SCHEMBL29871796 | 1.00 | JAK3 (1.00) | JAK3LCKEGFRBTK | |
| SCHEMBL20867721 | 0.94 | JAK3 (0.89) | JAK3LCKEGFRBTK | |
| SCHEMBL24891001 | 0.94 | JAK3 (0.88) | JAK3LCKEGFRBTK | |
| SCHEMBL21855176 | 0.93 | JAK3 (0.87) | JAK3LCKEGFRBTK | |
| SCHEMBL24833610 | 0.93 | JAK3 (0.87) | JAK3LCKEGFRBTK | |
| SCHEMBL25606430 | 0.93 | JAK3 (0.86) | JAK3LCKEGFRBTK | |
| SCHEMBL25603844 | 0.92 | JAK3 (0.88) | JAK3LCKEGFRBTK | |
| SCHEMBL25607907 | 0.92 | JAK3 (0.88) | JAK3LCKEGFRBTK | |
| SCHEMBL25605762 | 0.92 | JAK3 (0.84) | JAK3LCKEGFRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600732-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4678638-A1 | NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| EP-4570320-A2 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | Nurix Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| EP-4069237-B1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS INC (US) | 2025-04-09 | — | — | EP | disclosed |
| EP-4446324-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| WO-2024188209-A1 | NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-09-19 | — | — | WO | disclosed |
| CN-113412259-B | Difunctional compounds for degrading BTK via the ubiquitin proteasome pathway | 紐力克斯治疗公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240124475-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2024-04-18 | — | — | US | disclosed |
| WO-2021113557-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20200079754-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2020-03-12 | — | — | US | disclosed |
| US-20190100505-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2019-04-04 | — | — | US | disclosed |
| US-20180030027-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-02-01 | — | — | US | disclosed |
| US-9656988-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160355498-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. | 2016-12-08 | — | — | US | disclosed |
| EP-3077388-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | Pharmacyclics, LLC (US) | 2016-10-12 | — | — | EP | disclosed |
| US-9382246-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2016-07-05 | — | — | US | disclosed |
| WO-2015084998-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2015-06-11 | — | — | WO | disclosed |
| US-20150158865-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030027-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | JAK3 53/4885LCK 3/4885EGFR 692/4885 |
| US-20200079754-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LYN, LCK | JAK3 64/4885LCK 3/4885EGFR 705/4885 |
| US-20240124475-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | JAK3 623/4885LCK 125/4885EGFR 951/4885 |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, PSMB2, PSMB1 | JAK3 448/4885LCK 192/4885EGFR 1221/4885 |
| US-20160355498-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | JAK3 60/4885LCK 3/4885EGFR 700/4885 |
| US-20190100505-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | JAK3 60/4885LCK 3/4885EGFR 700/4885 |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, PSMB2, PSME3 | JAK3 362/4885LCK 177/4885EGFR 962/4885 |
| US-12600732-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, BCL9, BCL9L | JAK3 161/4885LCK 103/4885EGFR 809/4885 |
| US-20150158865-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | JAK3 60/4885LCK 3/4885EGFR 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.